MOTS-c · Research brief

MOTS-c Syringes Needles Supplies — Research Essentials

Q: What needle size is required for subcutaneous MOTS-c injections?

Subcutaneous MOTS-c injections require 28–31 gauge needles with 5/16-inch to 1/2-inch length, depending on injection site and subject body composition. The 28-gauge option offers the best balance between flow rate and injection site comfort, while 31-gauge needles reduce tissue trauma but require slower plunger depression. Needle length should match subcutaneous fat depth at the injection site — 5/16-inch works for lean subjects and thin-skinned areas like the abdomen, while 1/2-inch ensures proper subcutaneous delivery in subjects with higher body fat percentages.

Q: Can I use the same syringe for reconstitution and administration of MOTS-c?

No — proper MOTS-c handling requires separate syringes for reconstitution and administration. Reconstitution uses a 3ml syringe with an 18–20 gauge, 1.5-inch needle to draw bacteriostatic water and mix the lyophilised powder without creating mechanical shear stress. Administration requires a smaller insulin syringe (0.3–1ml) with a fixed 28–31 gauge needle for accurate subcutaneous dosing. Using the same syringe for both steps increases contamination risk from repeated vial punctures and causes peptide degradation from exposure to larger-bore needle turbulence during draws.

Q: How much do MOTS-c syringes needles supplies typically cost for a research study?

A complete MOTS-c syringes needles supplies kit for a single subject over a 4-week protocol (assuming three injections per week) costs approximately $45–75, depending on syringe type and supplier. Low-dead-space insulin syringes cost $0.80–1.20 each, standard insulin syringes $0.40–0.60 each, 3ml reconstitution syringes $0.30–0.50 each, and bacteriostatic water $8–15 per 30ml vial. Alcohol prep pads and sharps containers add another $10–15 for small studies. The primary cost driver is administration syringe selection — low-dead-space models cost 2–3 times more than standard insulin syringes but eliminate the 4–16% dosing error that occurs with small injection volumes.

Q: What are the risks of using the wrong needle gauge for MOTS-c injections?

Using needles smaller than 28-gauge (such as 32 or 33-gauge) creates excessive shear stress as the peptide solution is forced through the narrow bore, causing protein aggregation that reduces biological activity. A 2023 study in the Journal of Pharmaceutical Sciences found measurable peptide aggregation when pushing insulin through 32-gauge needles at standard injection speeds. Conversely, needles larger than 25-gauge increase injection site trauma and can cause intradermal rather than subcutaneous delivery if needle length is insufficient for the subject’s body composition. MOTS-c contains methionine residues particularly susceptible to oxidation under mechanical stress, making proper needle gauge selection critical for maintaining peptide integrity.

Q: How does low-dead-space syringe design improve MOTS-c dosing accuracy?

Low-dead-space (LDS) syringes feature a plunger tip that extends into the needle hub, reducing residual volume to less than 0.01ml compared to 0.04–0.08ml in standard insulin syringes. For MOTS-c doses of 0.1–0.5ml, standard syringe dead space represents 4–16% of the intended dose, introducing systematic underdosing that undermines dose-response studies and metabolic research outcomes. LDS syringes eliminate this error by delivering 98–99% of the drawn volume, ensuring actual administered doses match calculated protocol doses within ±5% accuracy.

Q: How does MOTS-c compare to other mitochondrial peptides in handling requirements?

MOTS-c shares similar reconstitution and storage requirements with other mitochondrial peptides like SS-31 (Elamipretide) and humanin — all require bacteriostatic water reconstitution, refrigerated storage at 2–8°C, and use within 28 days once mixed. However, MOTS-c is more oxidation-prone than SS-31 due to its methionine-rich sequence, making it more sensitive to mechanical shear stress during injection and requiring stricter needle gauge limits. Epithalon, another mitochondrial peptide, tolerates a wider temperature range during short-term storage but shares the same 28-day post-reconstitution stability window. The primary handling difference is concentration — MOTS-c is typically reconstituted to 2–5mg/ml for research use, while SS-31 protocols often use 10mg/ml, affecting injection volume and dead space considerations.

Q: What should I do if I see particulates in reconstituted MOTS-c solution?

Visible particulates indicate peptide aggregation from improper reconstitution technique or temperature excursion — do not inject the solution. Small white clumps or cloudiness that doesn’t clear after gentle swirling and 15 minutes of refrigeration at 2–8°C means the peptide structure is already compromised and the solution should be discarded. Proper reconstitution prevents this by injecting bacteriostatic water slowly down the vial wall rather than directly onto the lyophilised cake, avoiding mechanical agitation that denatures peptide bonds. If aggregation occurs consistently across multiple vials from the same batch, the issue may be peptide purity or storage conditions before reconstitution — contact your supplier for batch verification and replacement.

Q: Can I reuse needles for multiple MOTS-c injections to reduce costs?

No — needle reuse violates sterile technique, increases infection risk, and causes rapid needle dulling that creates tissue trauma and peptide shear stress. Even a single injection blunts the needle tip at the microscopic level, and subsequent insertions cause visible tissue tearing rather than clean puncture. More critically for peptide research, reusing needles introduces bacterial contamination from skin flora into the vial with every draw, degrading the bacteriostatic water’s preservative capacity and allowing bacterial growth that can denature the peptide within days. Single-use sterile needles cost $0.10–0.30 each — the false economy of reuse introduces variables that invalidate research outcomes worth thousands of dollars in time and materials.

Q: How long can reconstituted MOTS-c be stored before it degrades?

Reconstituted MOTS-c stored at 2–8°C in bacteriostatic water maintains stability for 28 days, after which the benzyl alcohol preservative degrades and bacterial contamination risk increases even under refrigeration. Peptide bioactivity may begin declining after 21 days due to oxidation of methionine residues, particularly if the vial has been punctured multiple times and exposed to air. For research protocols requiring injections beyond 28 days, reconstitute smaller batches more frequently rather than mixing a month’s supply at once. Temperature excursions above 8°C — even briefly during handling — accelerate degradation and can denature the peptide structure irreversibly, making strict cold chain maintenance essential throughout the storage period.

Q: What bacteriostatic water specifications are required for MOTS-c reconstitution?

MOTS-c reconstitution requires bacteriostatic water containing 0.9% benzyl alcohol as a preservative in USP sterile water — saline or sterile water without preservative cannot be used for multi-dose vials because they lack bacterial growth inhibition. The water must be stored at room temperature (not refrigerated) and discarded 28 days after the first needle puncture, as repeated vial access and air exposure degrade the benzyl alcohol’s antimicrobial effectiveness. Most suppliers provide bacteriostatic water in 10ml or 30ml multi-dose vials with rubber stoppers designed for repeated needle punctures — single-use ampules without preservative are appropriate only for immediate one-time reconstitution and complete administration within hours.

Real Peptides Research TeamEditorial

Updated April 9, 202612 min read

44 WORDS

Short answer

Key takeaways

MOTS-c syringes needles supplies require separate equipment for reconstitution (3ml syringe, 18–20 gauge needle) and administration (0.3–1ml insulin syringe, 28–31 gauge fixed needle) to prevent peptide degradation and ensure accurate dosing.
Low-dead-space insulin syringes reduce residual volume to less than 0.01ml, eliminating the 4–16% dose loss that occurs with standard syringes when administering MOTS-c volumes below 0.5ml.
Needle gauge directly affects peptide stability. Forcing MOTS-c through needles smaller than 28-gauge creates shear stress that can cause protein aggregation and loss of biological activity.
Reconstituted MOTS-c must be stored at 2–8°C and used within 28 days, as bacteriostatic water's benzyl alcohol degrades beyond that window even under refrigeration.
Proper draw technique. Tapping air bubbles to the top and expelling them before measuring dose. Prevents the 0.02–0.05ml underdosing that occurs when needle hubs contain air rather than peptide solution.
Bacteriostatic water must contain 0.9% benzyl alcohol and meet USP sterile water standards. Saline or sterile water without preservative cannot be used for multi-dose vials due to bacterial contamination risk.
The 16-amino-acid structure of MOTS-c, particularly its methionine residues, makes it more oxidation-prone than larger peptides like insulin. Mechanical stress during reconstitution or injection accelerates degradation.

Most peptide research protocols fail at the preparation stage, not during administration. A 2024 study from the University of Copenhagen found that improper reconstitution technique or incorrect syringe selection degraded peptide bioavailability by up to 40% before the compound ever reached the test subject. For researchers working with mitochondrial-derived peptides like MOTS-c, the margin for error is even narrower. The 16-amino-acid sequence is temperature-sensitive, prone to aggregation with mechanical stress, and requires specific handling protocols that generic lab supply guides don't cover.

We've supported hundreds of research teams sourcing MOTS-c syringes needles supplies for controlled studies. The gap between published results and lab replication often traces back to supply chain decisions made weeks before the first injection.

What syringes and needles are required for MOTS-c peptide research?

MOTS-c syringes needles supplies require insulin syringes with 0.3–1ml capacity, 28–31 gauge needles for subcutaneous administration, bacteriostatic water for reconstitution, and sterile alcohol prep pads. Standard protocol calls for separate reconstitution and administration syringes to prevent peptide degradation from repeated needle insertion through vial stoppers.

The most common supply error isn't contamination. It's using the wrong needle length for reconstitution versus administration. MOTS-c is typically supplied as lyophilised powder requiring reconstitution with bacteriostatic water before use. The reconstitution needle must be long enough to reach the bottom of the vial without creating excessive mechanical shear as you draw the bacteriostatic water and inject it slowly down the glass wall. Not directly onto the peptide cake. Most researchers default to the same 5/16-inch needle for both steps, which creates turbulence during mixing and pressure differentials during draws. This matters because MOTS-c contains methionine residues that oxidise under mechanical stress, reducing the peptide's ability to activate AMPK (AMP-activated protein kinase) signaling pathways in mitochondria.

Essential MOTS-c Syringes Needles Supplies for Research Protocols

Every MOTS-c research protocol requires four distinct supply categories: reconstitution equipment, administration equipment, storage containers, and sterile field materials. The FDA does not regulate peptides sold for research purposes under the same framework as pharmaceutical products, but labs following Good Laboratory Practice (GLP) standards maintain the same sterile technique protocols used in clinical settings. And that begins with proper syringe and needle selection.

For reconstitution, the standard is a 3ml Luer-Lok syringe paired with an 18–20 gauge, 1.5-inch needle. The larger bore allows bacteriostatic water to be drawn quickly without creating vacuum pressure inside the vial, and the length ensures you can angle the needle to inject fluid slowly down the vial wall rather than directly onto the lyophilised MOTS-c cake. Direct injection creates foam and denatures peptide bonds through mechanical agitation. A mistake that shows up as unexpectedly low bioavailability in downstream assays. Once reconstituted, MOTS-c should be stored at 2–8°C in the original sterile vial and used within 28 days, as bacterial growth inhibitors in bacteriostatic water degrade beyond that window even under refrigeration.

Administration requires a different setup entirely. Subcutaneous injection. The standard route for MOTS-c in animal models and human research. Uses insulin syringes with fixed 28–31 gauge needles and 0.3–1ml capacity. The 28-gauge option offers the best balance between injection comfort and flow rate for viscous solutions, while 31-gauge needles reduce injection site reactions but require slower plunger depression to prevent pressure buildup. Needle length depends on injection site and subject body composition: 5/16-inch (8mm) needles work for lean subjects and thin-skinned injection sites like the abdomen, while 1/2-inch (12.7mm) needles ensure subcutaneous delivery in subjects with higher body fat percentages. Researchers often overlook this detail and default to the shortest needle, which can result in intradermal rather than subcutaneous delivery. Changing absorption kinetics and making dose-response curves unreliable.

Sterile alcohol prep pads, sharps disposal containers, and nitrile gloves round out the essential MOTS-c syringes needles supplies list. Alcohol pads must contain 70% isopropyl alcohol. Not ethanol. As isopropyl achieves better bactericidal action against skin flora without leaving residue that can contaminate the injection site. Sharps containers must meet OSHA bloodborne pathogen standards even in non-clinical research settings, and disposal should follow institutional biosafety protocols. One frequently ignored detail: never recap needles after use. The CDC estimates that 30% of needlestick injuries occur during recapping. A completely avoidable risk with proper sharps container placement within arm's reach of the injection site.

How Needle Gauge and Syringe Volume Impact MOTS-c Research Outcomes

Needle gauge isn't just about injection comfort. It directly affects peptide stability during administration. MOTS-c, like all peptides, is a delicate protein structure susceptible to shear stress when forced through narrow openings at high velocity. A 2023 study published in the Journal of Pharmaceutical Sciences found that pushing insulin (a 51-amino-acid peptide) through a 32-gauge needle at standard injection speed caused measurable protein aggregation compared to 29-gauge needles. MOTS-c is smaller at 16 amino acids, but the methionine and cysteine residues in its sequence make it more oxidation-prone than insulin, meaning shear sensitivity may be even higher.

The mechanism is straightforward: as you depress the plunger, the liquid peptide solution accelerates through the needle bore, creating turbulent flow and localized high-pressure zones. These mechanical forces can partially unfold peptide chains, exposing hydrophobic regions that normally face inward. Once exposed, these regions attract each other and form aggregates. Clumps of tangled peptide that can't bind to their target receptors. In the case of MOTS-c, that target is the mitochondrial membrane, where the peptide modulates metabolic signaling through interactions with mitochondrial-encoded proteins. Aggregated peptide can't cross the membrane, rendering it biologically inert regardless of the dose administered.

Syringe volume matters for a different reason: dead space. Every syringe has a small volume of liquid that remains in the hub and needle after the plunger is fully depressed. Typically 0.02–0.08ml depending on design. For high-volume injections, this loss is negligible. But MOTS-c research doses often range from 0.1–0.5ml total volume, meaning dead space can represent 4–16% of the intended dose. If you're comparing treatment groups at 2.5mg versus 5mg MOTS-c and losing 0.05ml per injection to dead space, your actual delivered doses may differ significantly from your calculated doses. Introducing systematic error that undermines statistical power.

The solution is using low-dead-space (LDS) syringes, which reduce residual volume to less than 0.01ml. These syringes feature a plunger tip that extends into the needle hub, pushing nearly all the liquid out during injection. For MOTS-c research requiring precise dosing. Particularly dose-response studies or long-term metabolic investigations. LDS syringes are not optional. Suppliers like BD (Becton Dickinson) and Terumo manufacture insulin syringes with integrated LDS designs, typically labeled as 'low dead space' or 'fixed needle' models. Standard Luer-Lok syringes with detachable needles have the highest dead space and should be avoided for peptide administration entirely.

One practical detail most protocols omit: draw technique affects delivered dose as much as syringe design. After drawing your calculated MOTS-c dose from the vial, hold the syringe needle-up and tap the barrel to move air bubbles to the top. Then depress the plunger until a small bead of liquid appears at the needle tip. This confirms the needle and hub are filled with peptide solution rather than air. Only then should you measure your final dose against the syringe graduations. Researchers who skip this step and measure immediately after drawing often deliver 0.02–0.05ml less than intended because the needle hub is still filled with air.

MOTS-c Syringes Needles Supplies: Equipment Comparison

Choosing the right MOTS-c syringes needles supplies depends on research protocol requirements, injection volume, and subject characteristics. The table below compares standard options used in mitochondrial peptide research, with specific focus on features that affect MOTS-c stability and dosing accuracy.

Supply Type	Specification	Application	Considerations	Professional Assessment
Reconstitution Syringe	3ml Luer-Lok, 18–20 gauge, 1.5-inch needle	Drawing bacteriostatic water and reconstituting lyophilised MOTS-c	Larger bore prevents vacuum pressure; length allows angled injection down vial wall	Required for proper reconstitution technique. Prevents foam and mechanical peptide damage
Administration Syringe (Standard)	1ml insulin syringe, 28–29 gauge, 1/2-inch fixed needle	Subcutaneous MOTS-c injection in standard body composition subjects	Dead space 0.04–0.07ml; graduations typically 0.01ml	Acceptable for doses ≥0.3ml; dead space causes significant error below 0.2ml
Administration Syringe (LDS)	0.3–0.5ml insulin syringe, 29–31 gauge, 5/16–1/2-inch fixed needle, low dead space design	Precise subcutaneous dosing for dose-response studies	Dead space <0.01ml; finer graduations (0.005ml); higher cost per unit	Optimal for MOTS-c research requiring ±5% dosing accuracy or doses below 0.3ml
Reconstitution Needle (Separate)	18-gauge, 1.5-inch needle for 3ml syringe	Reconstitution only. Discarded after mixing	Reduces repeated punctures through vial stopper with administration needle	Best practice to prevent stopper coring and maintain sterility across multiple draws
Bacteriostatic Water	0.9% benzyl alcohol, USP sterile water, 10–30ml vial	Reconstituting lyophilised peptides for research use	Must be stored at room temperature; discard 28 days after first puncture	Standard diluent for all research peptides; benzyl alcohol prevents bacterial growth in multi-dose vials
Alcohol Prep Pads	70% isopropyl alcohol, individually wrapped sterile pads	Skin preparation before injection; vial stopper sterilization	Isopropyl preferred over ethanol for skin flora bactericidal action	Non-negotiable for sterile technique. Allow 30 seconds air-dry time before injection

What If: MOTS-c Syringes Needles Supplies Scenarios

What If You Don't Have Low-Dead-Space Syringes for a Dose-Response Study?

Use 0.5ml or 0.3ml insulin syringes instead of 1ml models to reduce absolute dead space volume, and overfill each syringe by 0.05ml to compensate for hub loss. Measure your intended dose plus the estimated dead space (0.04–0.07ml for standard insulin syringes), draw that total volume from the vial, then depress the plunger to your target dose marking after expelling air bubbles. This ensures the delivered dose matches your protocol even with residual hub volume. For doses below 0.15ml, this technique becomes unreliable. In those cases, source LDS syringes before proceeding or adjust your protocol to use higher concentrations and larger injection volumes that minimize dead space as a percentage of total dose.

What If the MOTS-c Powder Doesn't Fully Dissolve After Adding Bacteriostatic Water?

Do not shake the vial. Mechanical agitation denatures peptide bonds and creates aggregates that won't dissolve. Instead, gently swirl the vial in a circular motion for 30–60 seconds, then refrigerate at 2–8°C for 10–15 minutes. Cold temperature slows molecular motion and allows hydrophobic peptide regions to gradually hydrate without turbulence. If particulates remain after refrigeration, inspect under good lighting: small white clumps indicate aggregation from improper mixing technique (the peptide is likely compromised), while a clear solution with minor cloudiness often resolves with additional gentle swirling. Never use a solution with visible aggregates. The peptide structure is already damaged, and injection will deliver inactive protein fragments rather than functional MOTS-c.

What If You Accidentally Inject Air Into the Vial While Drawing Reconstituted MOTS-c?

Pressure buildup from injected air forces peptide solution back through the needle on subsequent draws, creating contamination risk and exposing the peptide to repeated shear stress. To equalize pressure without this risk, use a second sterile needle to vent the vial: insert an 18-gauge needle through the stopper without attaching a syringe, allowing air to escape as you draw your dose with the primary syringe. Remove the vent needle immediately after completing your draw to maintain sterility. For multi-dose vials used over several days, avoid venting entirely by matching the volume of air you inject with the volume of liquid you withdraw. This keeps internal pressure neutral and prevents the need for pressure equalization.

What If Your Institution Doesn't Allow Sharps Disposal Containers in Non-Clinical Labs?

Use a rigid, puncture-proof container with a secure lid that meets OSHA 29 CFR 1910.1030 standards for bloodborne pathogen waste, even if your research doesn't involve blood products. Acceptable alternatives include commercial sharps containers rated for lab use, heavy-duty plastic detergent bottles with screw caps (labeled clearly as sharps waste), or metal coffee cans with tight-fitting lids. The key requirement is that needles cannot penetrate the container wall and the lid cannot be easily removed once closed. Never use cardboard boxes, thin plastic containers, or any vessel that could be mistaken for general waste. Label the container 'SHARPS. DO NOT OPEN' in permanent marker, and coordinate with your institutional environmental health and safety office for pickup and disposal through licensed medical waste contractors.

The Practical Truth About MOTS-c Syringes Needles Supplies

Here's the honest answer: most researchers overspend on some supplies and underinvest in the ones that actually matter. Buying prefilled bacteriostatic water syringes marketed for peptide research costs 3–4 times more than drawing your own from a 30ml vial with a standard 3ml syringe. The convenience premium adds up across a multi-month study with no improvement in sterility or accuracy. At the same time, choosing standard insulin syringes over low-dead-space models to save $0.30 per injection introduces 5–15% dosing error that can completely obscure treatment effects in small-sample studies. We've reviewed this pattern across dozens of MOTS-c protocols: labs spend hundreds on expedited shipping for brand-name supplies that don't affect outcomes, then tolerate systematic dosing errors that invalidate months of work.

The bottom line: source your reconstitution supplies (syringes, needles, bacteriostatic water) from any reputable medical supply distributor that meets USP standards. Brand names don't matter here. But for administration syringes, invest in low-dead-space insulin syringes with fixed needles from manufacturers like BD or Terumo, particularly for doses below 0.5ml or any study where dose precision affects your primary endpoint. That $0.30 cost difference per injection is the best money you'll spend in the entire protocol.

One final detail that catches even experienced researchers: MOTS-c peptide from suppliers like Real Peptides arrives as lyophilised powder precisely because peptides in solution degrade rapidly even under refrigeration. Every additional day between reconstitution and injection increases the risk of oxidation, aggregation, and loss of bioactivity. If your protocol involves multiple injections per week over several weeks, reconstitute smaller batches more frequently rather than mixing a month's supply at once. The inconvenience of reconstituting every 7–10 days is minor compared to the risk of injecting degraded peptide halfway through your study timeline. For researchers interested in other mitochondrial and metabolic peptides, our catalog includes MOTS-c, Epithalon, and SS-31 (Elamipretide). All supplied with the same small-batch synthesis and purity verification standards.

The margin between valid research outcomes and wasted compounds comes down to supply decisions made before the first vial is ever opened. Choose equipment based on the biology of the peptide you're handling, not the lowest line-item cost or the flashiest marketing. MOTS-c deserves the same handling rigor as any clinical-grade biologic. Because mechanistically, it is one.

References

Peer-reviewed sources on MOTS-c indexed in PubMed, listed for research context. Real Peptides supplies MOTS-c for laboratory research use only.

MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free radical biology & medicine, 2026. PMID 41520850. doi:10.1016/j.freeradbiomed.2026.01.002
Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction. Biomedicines, 2026. PMID 42193373. doi:10.3390/biomedicines14051048
MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation. Autophagy, 2026. PMID 42153537. doi:10.1080/15548627.2026.2677180
Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis. Free radical biology & medicine, 2026. PMID 41933740. doi:10.1016/j.freeradbiomed.2026.03.074
MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy. Free radical biology & medicine, 2026. PMID 41654147. doi:10.1016/j.freeradbiomed.2026.01.064
Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Experimental & molecular medicine, 2025. PMID 40855115. doi:10.1038/s12276-025-01521-1
MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free radical biology & medicine, 2025. PMID 41043625. doi:10.1016/j.freeradbiomed.2025.09.056
MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. American journal of respiratory cell and molecular biology, 2025. PMID 40035775. doi:10.1165/rcmb.2024-0533OC

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions